Edward Md Kaye Sells 25,000 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Key Points

• Director Edward Md Kaye sold 25,000 shares of Stoke Therapeutics at an average price of $30.00, resulting in a total transaction of $750,000 and a 33.73% decrease in his ownership.
• Stoke Therapeutics' stock has a market cap of $1.65 billion, with its shares recently trading at $30.19, representing a 52 week range from $5.35 to $32.40.
• Analysts have mixed ratings on Stoke Therapeutics, with a consensus rating of “Buy” and a target price averaging $27.43, while some firms maintain lower price targets of $24.00 and $28.00.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) Director Edward Md Kaye sold 25,000 shares of the business's stock in a transaction that occurred on Wednesday, October 8th. The shares were sold at an average price of $30.00, for a total transaction of $750,000.00. Following the sale, the director owned 49,124 shares of the company's stock, valued at $1,473,720. This trade represents a 33.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Stoke Therapeutics Trading Up 1.0%

Shares of NASDAQ STOK traded up $0.29 during mid-day trading on Friday, reaching $30.19. The company had a trading volume of 1,331,021 shares, compared to its average volume of 859,518. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $32.40. The business's 50-day moving average is $20.63 and its 200-day moving average is $13.67. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of 35.52 and a beta of 1.24.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.17. The firm had revenue of $13.82 million during the quarter, compared to analyst estimates of $31.51 million. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. As a group, equities research analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on STOK. Weiss Ratings reissued a "sell (d+)" rating on shares of Stoke Therapeutics in a report on Wednesday. BTIG Research set a $28.00 price target on Stoke Therapeutics and gave the company a "buy" rating in a report on Monday, August 18th. Chardan Capital reissued a "buy" rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, August 13th. Wedbush increased their price target on Stoke Therapeutics from $16.00 to $22.00 and gave the company an "outperform" rating in a research report on Wednesday, August 13th. Finally, Needham & Company LLC raised their price objective on Stoke Therapeutics from $22.00 to $35.00 and gave the stock a "buy" rating in a research note on Friday. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Stoke Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $27.43.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Wellington Management Group LLP lifted its stake in shares of Stoke Therapeutics by 0.9% in the first quarter. Wellington Management Group LLP now owns 135,960 shares of the company's stock valued at $904,000 after purchasing an additional 1,148 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Stoke Therapeutics by 5.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company's stock worth $162,000 after buying an additional 1,149 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company's stock valued at $48,000 after purchasing an additional 1,668 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Stoke Therapeutics by 14.1% in the second quarter. The Manufacturers Life Insurance Company now owns 15,099 shares of the company's stock valued at $171,000 after acquiring an additional 1,862 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its holdings in shares of Stoke Therapeutics by 33.2% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company's stock worth $108,000 after purchasing an additional 2,384 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.